Last reviewed · How we verify
NCT07221565: QSIT
Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting
Phase 1, PHASE2 trial testing Low-Frequency Electromagnetic Resonance Therapy (LF-EMR) in Systemic Lupus Erythematosus in 120 participants. Enrolling by invitation.
23 October 2034
Quick facts
| Lead sponsor | Truway Health, Inc. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 23 October 2025 |
| Primary completion | 23 October 2034 |
| Estimated completion | 23 October 2034 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)
- Sham Resonance Device (Inactive Control)
- Low-Dose Naltrexone (LDN) — full drug profile →
Conditions studied
- Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
Sponsor
Truway Health, Inc. — full company profile →
Who can join
Eligibility, any sex, with Systemic Lupus Erythematosus or Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07221565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erythematosus
Currently open trials in the same condition.
- NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
- NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting
Other Truway Health, Inc. trials
Trials by the same sponsor.
- NCT07472023 — Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss · EARLY_PHASE1 · enrolling by invitation
- NCT07382804 — Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification · NA · enrolling by invitation
- NCT07321028 — Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001) · EARLY_PHASE1 · enrolling by invitation
- NCT07217730 — Healthcare Integrity & Anti-Fraud Enforcement · enrolling by invitation
- NCT07214896 — Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings · Phase 2 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07221565 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Truway Health, Inc.
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07221565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing